VEGF Conjugation for Scaffold Vascularization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for creating artificial organs face challenges in achieving sufficient vascularization and blood circulation due to limited binding sites for vascular endothelial growth factor (VEGF) in 3D scaffold structures, which hinders long-term survival of cells within these constructs.
Innovation Solution
Conjugation of VEGF with targeting moieties such as collagen binding proteins (CBP) and avidin/streptavidin, utilizing click chemistry and multi-antigen peptides (MAP) to create compositions that allow for higher concentrations and localized binding of VEGF on collagen IV, enabling robust protein-protein interactions and self-assembly into 3D structures.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If traditional recombinant expression methods are used to express VEGF, then the VEGF can be produced, but the concentration and localization of VEGF on scaffold surfaces is insufficient
Solution Approach 1:
The patent creates a composite structure by conjugating VEGF with targeting moieties (such as collagen-binding peptides or hyaluronic acid-binding peptides) to form a multifunctional molecule that can simultaneously bind to the scaffold matrix and deliver growth factor activity. This composite approach allows VEGF to be anchored at high concentrations on the scaffold surface while maintaining its biological function, thereby resolving the contradiction between achieving high VEGF concentration and ensuring long-term cell survival.
Solution Approach 2:
The patent implements local quality by using targeting moieties that specifically bind to certain components of the scaffold matrix (e.g., collagen or hyaluronic acid) to create localized zones of high VEGF concentration at the scaffold surface. This localized delivery ensures that VEGF is concentrated precisely where it is needed for angiogenesis and cell survival, rather than being uniformly distributed or lost in the culture medium.
2Quantity of substance
If multiple targeting moieties are conjugated to VEGF to increase binding capacity, then the binding affinity increases, but the device complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the targeting function into separate, modular targeting moieties that can be independently selected and conjugated to VEGF. Each targeting moiety can be optimized for binding to specific scaffold components, and multiple different targeting moieties can be combined on a single VEGF molecule. This modular approach increases binding capacity while managing complexity through standardized conjugation methods and interchangeable targeting domains.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly enhances the binding affinity and concentration of VEGF on scaffold surfaces, promoting angiogenesis and ensuring proper vasculature formation within artificial organs, overcoming the limitations of traditional recombinant expression methods.
Implementation Method 1
the targeting moiety is a collagen binding protein (CBP)... allows higher concentrations of the GF at specific locations (e.g., localized at sites with collagen IV)
Implementation Method 2
the present invention features a composition comprising a growth factor (GF) conjugated to one or more avidin or streptavidin proteins
Implementation Method 3
utilizing click chemistry and multi-antigen peptides (MAP) to create compositions that allow for higher concentrations and localized binding of VEGF
Data Source
AI summary
The present invention features compositions and methods for the localization and concentration of various growth factors (e.g., vascular endothelial growth factor (VEGF), or an angiopoietin-1 (ANG1) protein, or an angiopoietin-2 (ANG2) protein) within a scaffold structure. The present invention may also be used to promote the rebuilding of vasculature on de-celled organs (e.g., a kidney) or artificial organs.